This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Malabsorption as a Cause of Iron Treatment Failure in Infants

This study has been completed.
Information provided by:
HaEmek Medical Center, Israel Identifier:
First received: April 4, 2007
Last updated: NA
Last verified: January 2007
History: No changes posted
Infants should receive prophylacatic iron supplementation since age 4 months till one year. Patients suffering from malabsorption, mainly Giardia infestation may develop iron deficiency resistent to further iron treatment. The purpose of this study is to assess the incidence of malabsorption in those infants and to examine the results of empiric treatment with metronidazole.

Condition Intervention
Iron Deficiency Malabsorption Drug: Metronidazole Procedure: Blood tests

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Malabsorption as a Cause of Iron Treatment Failure in Infants - A Clinical Observational Study

Resource links provided by NLM:

Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • Hgb level

Secondary Outcome Measures:
  • Iron level
  • Ferritin Level

Estimated Enrollment: 100
Study Start Date: May 2006
Study Completion Date: July 2006

Ages Eligible for Study:   6 Months to 4 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All infants referred to the Pediatric Hematology Unit because lack of response to iron treatment.

Exclusion Criteria:

  • Patients diagnosed with specific malabsorption causes like Celiac or Cystic Fibrosis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00456729

Pediatric Hematology Unit and Pediatric Dpt B - HaEmek Medical Center
Afula, Israel, 18101
Sponsors and Collaborators
HaEmek Medical Center, Israel
Study Director: Ariel Koren, MD Pediatric Hematology Unit, Ha'Emek Medical Center
Principal Investigator: Carina Levin, MD Pediatric Hematology Unit - Ha'Emek Medical Center
Principal Investigator: Tania Hanchis, MD Pediatric Dpt B - Ha'Emek Medical Center
  More Information Identifier: NCT00456729     History of Changes
Other Study ID Numbers: 4150905.EMC
Study First Received: April 4, 2007
Last Updated: April 4, 2007

Keywords provided by HaEmek Medical Center, Israel:
Iron deficiency

Additional relevant MeSH terms:
Anemia, Iron-Deficiency
Malabsorption Syndromes
Anemia, Hypochromic
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents processed this record on September 21, 2017